{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:25Z","timestamp":1787003065551,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2010804"],"award-info":[{"award-number":["W81XWH2010804"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64983-x","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:18:48Z","timestamp":1763133528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The SLC1A1\/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs"],"prefix":"10.1038","volume":"16","author":[{"given":"Treg","family":"Grubb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooneh","family":"Koochaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatme","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerise","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-5947","authenticated-orcid":false,"given":"Eduard","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesminara","family":"Khatun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleigh","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Dubasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2170-0208","authenticated-orcid":false,"given":"David A.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyanu","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghvendra M.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-9860","authenticated-orcid":false,"given":"Jesse A.","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-3479","authenticated-orcid":false,"given":"Ritesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-8824","authenticated-orcid":false,"given":"A. Ari","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7450-2589","authenticated-orcid":false,"given":"John M.","family":"Asara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-0283","authenticated-orcid":false,"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-7963","authenticated-orcid":false,"given":"Sakari","family":"Vanharanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun R.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-4856","authenticated-orcid":false,"suffix":"Jr.","given":"William G.","family":"Kaelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-188X","authenticated-orcid":false,"given":"Abhishek A.","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"64983_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"64983_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326.e5 (2018).","journal-title":"Cell Rep."},{"key":"64983_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin, W. G. Jr. The von Hippel\u2013Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865\u2013873 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"64983_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464\u2013468 (2001).","journal-title":"Science"},{"key":"64983_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468\u2013472 (2001).","journal-title":"Science"},{"key":"64983_CR6","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"64983_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","volume":"11","author":"JD Gordan","year":"2007","unstructured":"Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335\u2013347 (2007).","journal-title":"Cancer Cell"},{"key":"64983_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"64983_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"64983_CR10","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. N. Engl. J. Med 385, 2036\u20132046 (2021).","journal-title":"N. Engl. J. Med"},{"key":"64983_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cancergen.2015.02.008","volume":"208","author":"L Liao","year":"2015","unstructured":"Liao, L., Testa, J. R. & Yang, H. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet. 208, 206\u2013214 (2015).","journal-title":"Cancer Genet."},{"key":"64983_CR12","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1073\/pnas.0810067106","volume":"106","author":"X Xia","year":"2009","unstructured":"Xia, X. et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 106, 4260\u20134265 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64983_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539\u2013542 (2011).","journal-title":"Nature"},{"key":"64983_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature08672","volume":"463","author":"GL Dalgliesh","year":"2010","unstructured":"Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360\u2013363 (2010).","journal-title":"Nature"},{"key":"64983_CR15","doi-asserted-by":"crossref","unstructured":"Chakraborty, A. A. et al. HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci. Transl. Med. 9, eaal5272 (2017).","DOI":"10.1126\/scitranslmed.aal5272"},{"key":"64983_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"64983_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"64983_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.CD-17-0375","volume":"7","author":"X Yao","year":"2017","unstructured":"Yao, X. et al. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 7, 1284\u20131305 (2017).","journal-title":"Cancer Discov."},{"key":"64983_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-17-1211","volume":"8","author":"P Rodrigues","year":"2018","unstructured":"Rodrigues, P. et al. NF-kappaB-dependent lymphoid enhancer co-option promotes renal carcinoma metastasis. Cancer Discov. 8, 850\u2013865 (2018).","journal-title":"Cancer Discov."},{"key":"64983_CR20","doi-asserted-by":"publisher","first-page":"110424","DOI":"10.1016\/j.ygeno.2022.110424","volume":"114","author":"FC Huo","year":"2022","unstructured":"Huo, F. C., Xie, M., Zhu, Z. M., Zheng, J. N. & Pei, D. S. SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT. Genomics 114, 110424 (2022).","journal-title":"Genomics"},{"key":"64983_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05677-4","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Serine hydroxymethyltransferase 2 knockdown induces apoptosis in ccRCC by causing lysosomal membrane permeabilization via metabolic reprogramming. Cell Death Dis. 14, 144 (2023).","journal-title":"Cell Death Dis."},{"key":"64983_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aap8411","volume":"361","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361, 290\u2013295 (2018).","journal-title":"Science"},{"key":"64983_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112945","volume":"42","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. HIF-1alpha drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. Cell Rep. 42, 112945 (2023).","journal-title":"Cell Rep."},{"key":"64983_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin, W. G. Jr. & Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393\u2013402 (2008).","journal-title":"Mol. Cell"},{"key":"64983_CR25","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1046\/j.1471-4159.2003.01630.x","volume":"84","author":"Y Chen","year":"2003","unstructured":"Chen, Y. & Swanson, R. A. The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J. Neurochem. 84, 1332\u20131339 (2003).","journal-title":"J. Neurochem."},{"key":"64983_CR26","doi-asserted-by":"publisher","first-page":"31891","DOI":"10.1074\/jbc.274.45.31891","volume":"274","author":"RL O\u2019Kane","year":"1999","unstructured":"O\u2019Kane, R. L., Martinez-Lopez, I., DeJoseph, M. R., Vina, J. R. & Hawkins, R. A. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J. Biol. Chem. 274, 31891\u201331895 (1999).","journal-title":"J. Biol. Chem."},{"key":"64983_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41556-018-0118-z","volume":"20","author":"J Garcia-Bermudez","year":"2018","unstructured":"Garcia-Bermudez, J. et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775\u2013781 (2018).","journal-title":"Nat. Cell Biol."},{"key":"64983_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s42255-020-00315-1","volume":"2","author":"S Raho","year":"2020","unstructured":"Raho, S. et al. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth. Nat. Metab. 2, 1373\u20131381 (2020).","journal-title":"Nat. Metab."},{"key":"64983_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2017.03.023","volume":"169","author":"JR Cantor","year":"2017","unstructured":"Cantor, J. R. et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell 169, 258\u2013272.e17 (2017).","journal-title":"Cell"},{"key":"64983_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38120-5","volume":"14","author":"B Qiu","year":"2023","unstructured":"Qiu, B. & Boudker, O. Symport and antiport mechanisms of human glutamate transporters. Nat. Commun. 14, 2579 (2023).","journal-title":"Nat. Commun."},{"key":"64983_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1172\/JCI44474","volume":"121","author":"CG Bailey","year":"2011","unstructured":"Bailey, C. G. et al. Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J. Clin. Invest. 121, 446\u2013453 (2011).","journal-title":"J. Clin. Invest."},{"key":"64983_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41596-018-0102-x","volume":"14","author":"M Yuan","year":"2019","unstructured":"Yuan, M. et al. Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC-MS\/MS. Nat. Protoc. 14, 313\u2013330 (2019).","journal-title":"Nat. Protoc."},{"key":"64983_CR33","doi-asserted-by":"publisher","first-page":"W127","DOI":"10.1093\/nar\/gks374","volume":"40","author":"J Xia","year":"2012","unstructured":"Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D. & Wishart, D. S. MetaboAnalyst 2.0\u2013a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 40, W127\u2013W133 (2012).","journal-title":"Nucleic Acids Res."},{"key":"64983_CR34","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64983_CR35","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1093\/emboj\/16.13.3822","volume":"16","author":"P Peghini","year":"1997","unstructured":"Peghini, P., Janzen, J. & Stoffel, W. Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J. 16, 3822\u20133832 (1997).","journal-title":"EMBO J."},{"key":"64983_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1517\/14728220902926127","volume":"13","author":"L Bunch","year":"2009","unstructured":"Bunch, L., Erichsen, M. N. & Jensen, A. A. Excitatory amino acid transporters as potential drug targets. Expert Opin. Ther. Targets 13, 719\u2013731 (2009).","journal-title":"Expert Opin. Ther. Targets"},{"key":"64983_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1471-4159.2006.03978.x","volume":"98","author":"A Nieoullon","year":"2006","unstructured":"Nieoullon, A. et al. The neuronal excitatory amino acid transporter EAAC1\/EAAT3: Does it represent a major actor at the brain excitatory synapse? J. Neurochem 98, 1007\u20131018 (2006).","journal-title":"J. Neurochem"},{"key":"64983_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.pharmthera.2005.01.002","volume":"107","author":"RJ Bridges","year":"2005","unstructured":"Bridges, R. J. & Esslinger, C. S. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharm. Ther. 107, 271\u2013285 (2005).","journal-title":"Pharm. Ther."},{"key":"64983_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.neuropharm.2005.08.009","volume":"49","author":"CS Esslinger","year":"2005","unstructured":"Esslinger, C. S. et al. The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology 49, 850\u2013861 (2005).","journal-title":"Neuropharmacology"},{"key":"64983_CR40","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1021\/acsmedchemlett.0c00342","volume":"11","author":"N Liu","year":"2020","unstructured":"Liu, N., Jensen, A. A. & Bunch, L. Beta-indolyloxy functionalized aspartate analogs as inhibitors of the excitatory amino acid transporters (EAATs). ACS Med Chem. Lett. 11, 2212\u20132220 (2020).","journal-title":"ACS Med Chem. Lett."},{"key":"64983_CR41","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1016\/S0960-894X(02)00520-6","volume":"12","author":"T Denton","year":"2002","unstructured":"Denton, T., Seib, T., Bridges, R. & Thompson, C. Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors. Bioorg. Med. Chem. Lett. 12, 3209\u20133213 (2002).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"64983_CR42","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/S0960-894X(00)00487-X","volume":"10","author":"K Shimamoto","year":"2000","unstructured":"Shimamoto, K. et al. Syntheses of optically pure beta-hydroxyaspartate derivatives as glutamate transporter blockers. Bioorg. Med. Chem. Lett. 10, 2407\u20132410 (2000).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"64983_CR43","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1021\/acschemneuro.9b00447","volume":"10","author":"P Wu","year":"2019","unstructured":"Wu, P., Bjorn-Yoshimoto, W. E., Staudt, M., Jensen, A. A. & Bunch, L. Identification and structure-activity relationship study of imidazo[1,2-a]pyridine-3-amines as first selective inhibitors of excitatory amino acid transporter subtype 3 (EAAT3). ACS Chem. Neurosci. 10, 4414\u20134429 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"64983_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","volume":"17","author":"PA Gameiro","year":"2013","unstructured":"Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17, 372\u2013385 (2013).","journal-title":"Cell Metab."},{"key":"64983_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature17393","volume":"532","author":"L Jiang","year":"2016","unstructured":"Jiang, L. et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255\u2013258 (2016).","journal-title":"Nature"},{"key":"64983_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature10602","volume":"481","author":"CM Metallo","year":"2011","unstructured":"Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380\u2013384 (2011).","journal-title":"Nature"},{"key":"64983_CR47","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1172\/JCI87800","volume":"127","author":"A Okazaki","year":"2017","unstructured":"Okazaki, A. et al. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J. Clin. Invest. 127, 1631\u20131645 (2017).","journal-title":"J. Clin. Invest."},{"key":"64983_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","volume":"16","author":"WM Linehan","year":"2019","unstructured":"Linehan, W. M. & Ricketts, C. J. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat. Rev. Urol. 16, 539\u2013552 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"64983_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm.3029","volume":"19","author":"S Vanharanta","year":"2013","unstructured":"Vanharanta, S. et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat. Med. 19, 50\u201356 (2013).","journal-title":"Nat. Med."},{"key":"64983_CR50","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/0008-5472.CAN-20-0617","volume":"81","author":"W Guo","year":"2021","unstructured":"Guo, W. et al. Dysregulated glutamate transporter SLC1A1 propels cystine uptake via Xc(-) for glutathione synthesis in lung cancer. Cancer Res. 81, 552\u2013566 (2021).","journal-title":"Cancer Res."},{"key":"64983_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103614","volume":"72","author":"J Xiong","year":"2021","unstructured":"Xiong, J. et al. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. EBioMedicine 72, 103614 (2021).","journal-title":"EBioMedicine"},{"key":"64983_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41422-022-00650-w","volume":"32","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Res. 32, 638\u2013658 (2022).","journal-title":"Cell Res."},{"key":"64983_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2042114","volume":"2021","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Identification of prognostic metabolism-related genes in clear cell renal cell carcinoma. J. Oncol. 2021, 2042114 (2021).","journal-title":"J. Oncol."},{"key":"64983_CR54","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3906\/sag-1808-130","volume":"49","author":"S Ergun","year":"2019","unstructured":"Ergun, S., Gunes, S., Buyukalpelli, R. & Aydin, O. Glutamate transporter SLC1A1 is associated with clear cell renal cell carcinoma. Turk. J. Med. Sci. 49, 531\u2013537 (2019).","journal-title":"Turk. J. Med. Sci."},{"key":"64983_CR55","doi-asserted-by":"publisher","first-page":"110569","DOI":"10.1016\/j.celrep.2022.110569","volume":"38","author":"JC Smith","year":"2022","unstructured":"Smith, J. C. & Sheltzer, J. M. Genome-wide identification and analysis of prognostic features in human cancers. Cell Rep. 38, 110569 (2022).","journal-title":"Cell Rep."},{"key":"64983_CR56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc.2017.32","volume":"17","author":"WG Kaelin Jr.","year":"2017","unstructured":"Kaelin, W. G. Jr. Common pitfalls in preclinical cancer target validation. Nat. Rev. Cancer 17, 425\u2013440 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"64983_CR57","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104\u2013116 (2016).","journal-title":"Cancer Cell"},{"key":"64983_CR58","doi-asserted-by":"crossref","unstructured":"Bezwada, D. et al. Mitochondrial complex I promotes kidney cancer metastasis. Nature 633, 923\u2013931 (2024).","DOI":"10.1038\/s41586-024-07812-3"},{"key":"64983_CR59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-05661-6","volume":"614","author":"CR Bartman","year":"2023","unstructured":"Bartman, C. R. et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature 614, 349\u2013357 (2023).","journal-title":"Nature"},{"key":"64983_CR60","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.celrep.2014.10.018","volume":"9","author":"DA Orlando","year":"2014","unstructured":"Orlando, D. A. et al. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. Cell Rep. 9, 1163\u20131170 (2014).","journal-title":"Cell Rep."},{"key":"64983_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"64983_CR62","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"64983_CR63","doi-asserted-by":"publisher","first-page":"D463","DOI":"10.1093\/nar\/gkv1042","volume":"44","author":"M Sud","year":"2016","unstructured":"Sud, M. et al. Metabolomics Workbench: an international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res. 44, D463\u2013470 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64983-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64983-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64983-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:06:12Z","timestamp":1763510772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64983-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64983"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64983-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest with the data presented in this study. W.G.K. is a paid advisor to Casdin Capital, Circle Pharma, Fibrogen, Nextech and Tango Therapeutics and serves on the boards of IcoOVir Bio, Lifemine Therapeutics and Eli Lilly. T.K.C. reports institutional and\/or personal, paid and\/or unpaid support for research, advisory boards, consultancy and\/or honoraria past 5 years and ongoing, from Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work; institutional patents filed on molecular alterations and immunotherapy response\/toxicity and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura; committee service at NCCN, GU Steering Committee, ASCO\/ESMO, ACCRU, KidneyCan; medical writing and editorial assistance support may have been funded by Communications companies in part; no speaker\u2019s bureau; mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/Foreign Components; The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter of T.K.C\u2019s findings (not related to this study). T.K.C. is supported in part by the Dana-Farber\/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. S.S. reports receiving commercial research grants from Bristol-Myers Squibb, AstraZeneca, Exelixis and Novartis; is a consultant\/advisory board member for Merck, AstraZeneca, Bristol-Myers Squibb, CRISPR Therapeutics AG, AACR and NCI; receives royalties from Biogenex; and mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/Foreign Components. R.R.K reports consulting for Eisai, and institutional research funding from Pfizer, Takeda, Novartis, Exelixis, Xencor, Arsenal Bio and Allogene Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10012"}}